LeMaitre Vascular Inc. (NASDAQ:LMAT) was downgraded by research analysts at Sidoti from a “buy” rating to a “neutral” rating in a research report issued to clients and investors on Thursday.

Several other brokerages have also recently issued reports on LMAT. Brean Capital increased their target price on shares of LeMaitre Vascular from $17.50 to $20.00 and gave the stock a “buy” rating in a report on Thursday, July 28th. Zacks Investment Research cut shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a report on Wednesday, July 6th. Canaccord Genuity set a $19.00 price target on shares of LeMaitre Vascular and gave the company a “buy” rating in a report on Thursday, July 28th. Finally, Barrington Research raised their price target on shares of LeMaitre Vascular from $18.50 to $20.00 and gave the company an “outperform” rating in a report on Thursday, July 28th. One analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average price target of $18.94.

Analyst Recommendations for LeMaitre Vascular (NASDAQ:LMAT)

Shares of LeMaitre Vascular (NASDAQ:LMAT) traded down 2.96% during mid-day trading on Thursday, reaching $20.98. 126,581 shares of the company traded hands. The firm has a 50-day moving average price of $18.73 and a 200 day moving average price of $15.92. LeMaitre Vascular has a 52 week low of $11.80 and a 52 week high of $22.50. The firm has a market capitalization of $387.37 million, a price-to-earnings ratio of 42.13 and a beta of 0.51.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/22/lemaitre-vascular-inc-lmat-downgraded-to-neutral-at-sidoti.html

LeMaitre Vascular (NASDAQ:LMAT) last issued its earnings results on Wednesday, July 27th. The company reported $0.14 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.11 by $0.03. LeMaitre Vascular had a net margin of 11.43% and a return on equity of 11.90%. The company had revenue of $22.40 million for the quarter, compared to analysts’ expectations of $21.59 million. LeMaitre Vascular’s revenue was up 12.6% on a year-over-year basis. On average, analysts anticipate that LeMaitre Vascular will post $0.55 earnings per share for the current year.

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, September 6th. Investors of record on Monday, August 22nd were given a $0.045 dividend. This represents a $0.18 annualized dividend and a dividend yield of 0.83%. The ex-dividend date of this dividend was Thursday, August 18th. LeMaitre Vascular’s payout ratio is currently 36.73%.

In related news, insider Peter R. Gebauer sold 30,000 shares of the stock in a transaction that occurred on Thursday, July 28th. The shares were sold at an average price of $16.47, for a total value of $494,100.00. Following the completion of the transaction, the insider now directly owns 25,374 shares of the company’s stock, valued at approximately $417,909.78. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO George W. Lemaitre sold 8,927 shares of the stock in a transaction that occurred on Monday, August 22nd. The shares were sold at an average price of $17.39, for a total transaction of $155,240.53. Following the completion of the transaction, the chief executive officer now directly owns 3,491,564 shares of the company’s stock, valued at $60,718,297.96. The disclosure for this sale can be found here. 28.90% of the stock is currently owned by corporate insiders.

Several institutional investors have recently made changes to their positions in LMAT. Blair William & Co. IL raised its position in shares of LeMaitre Vascular by 0.9% in the second quarter. Blair William & Co. IL now owns 16,389 shares of the company’s stock valued at $234,000 after buying an additional 140 shares during the last quarter. Nationwide Fund Advisors raised its position in shares of LeMaitre Vascular by 6.7% in the second quarter. Nationwide Fund Advisors now owns 9,293 shares of the company’s stock valued at $133,000 after buying an additional 580 shares during the last quarter. Renaissance Technologies LLC raised its position in shares of LeMaitre Vascular by 0.6% in the first quarter. Renaissance Technologies LLC now owns 124,600 shares of the company’s stock valued at $1,934,000 after buying an additional 800 shares during the last quarter. American International Group Inc. raised its position in shares of LeMaitre Vascular by 11.7% in the second quarter. American International Group Inc. now owns 7,775 shares of the company’s stock valued at $111,000 after buying an additional 817 shares during the last quarter. Finally, Metropolitan Life Insurance Co. NY raised its position in shares of LeMaitre Vascular by 19.2% in the second quarter. Metropolitan Life Insurance Co. NY now owns 11,330 shares of the company’s stock valued at $162,000 after buying an additional 1,826 shares during the last quarter. 59.88% of the stock is owned by hedge funds and other institutional investors.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc is a provider of medical devices for the treatment of peripheral vascular disease. The Company and its subsidiaries develop, manufacture and market medical devices and implants used primarily in the field of vascular surgery. It operates in the design, marketing, sales and technical support of medical devices and implants for the treatment of peripheral vascular disease industry segment.

5 Day Chart for NASDAQ:LMAT

Receive News & Ratings for LeMaitre Vascular Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular Inc. and related companies with MarketBeat.com's FREE daily email newsletter.